119 related articles for article (PubMed ID: 15841388)
1. A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients.
Gartner W; Mineva I; Daneva T; Baumgartner-Parzer S; Niederle B; Vierhapper H; Weissel M; Wagner L
Hum Genet; 2005 Jul; 117(2-3):143-53. PubMed ID: 15841388
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
[TBL] [Abstract][Full Text] [Related]
3. Investigation of loss of heterozygosity and SNP frequencies in the RET gene in papillary thyroid carcinoma.
Stephens LA; Powell NG; Grubb J; Jeremiah SJ; Bethel JA; Demidchik EP; Bogdanova TI; Tronko MD; Thomas GA
Thyroid; 2005 Feb; 15(2):100-4. PubMed ID: 15753666
[TBL] [Abstract][Full Text] [Related]
4. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
5. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Kodama Y; Asai N; Kawai K; Jijiwa M; Murakumo Y; Ichihara M; Takahashi M
Cancer Sci; 2005 Mar; 96(3):143-8. PubMed ID: 15771616
[TBL] [Abstract][Full Text] [Related]
6. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
7. Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display.
Musholt TJ; Hanack J; Brehm C; von Wasielewski R; Musholt PB
World J Surg; 2005 Apr; 29(4):472-82. PubMed ID: 15776290
[TBL] [Abstract][Full Text] [Related]
8. Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation: implications for newly generated chi-like sequence.
Veljkovic E; Dzodic R; Neskovic G; Stanojevic B; Milovanovic Z; Opric M; Dimitrijevic B
Med Oncol; 2004; 21(4):319-24. PubMed ID: 15579915
[TBL] [Abstract][Full Text] [Related]
9. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A.
Chung YJ; Kim HH; Kim HJ; Min YK; Lee MS; Lee MK; Kim KW; Ki CS; Kim JW; Chung JH
Thyroid; 2004 Oct; 14(10):813-8. PubMed ID: 15588376
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.
Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM
Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382
[TBL] [Abstract][Full Text] [Related]
11. Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma.
Huang SC; Torres-Cruz J; Pack SD; Koch CA; Vortmeyer AO; Mannan P; Lubensky IA; Gagel RF; Zhuang Z
J Clin Endocrinol Metab; 2003 Jan; 88(1):459-63. PubMed ID: 12519890
[TBL] [Abstract][Full Text] [Related]
12. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
[TBL] [Abstract][Full Text] [Related]
13. Minireview: RET: normal and abnormal functions.
Santoro M; Melillo RM; Carlomagno F; Vecchio G; Fusco A
Endocrinology; 2004 Dec; 145(12):5448-51. PubMed ID: 15331579
[TBL] [Abstract][Full Text] [Related]
14. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
15. Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome.
Poturnajova M; Altanerova V; Kostalova L; Breza J; Altaner C
J Mol Med (Berl); 2005 Apr; 83(4):287-95. PubMed ID: 15592804
[TBL] [Abstract][Full Text] [Related]
16. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
J Mol Med (Berl); 1996 Oct; 74(10):617-21. PubMed ID: 8912182
[TBL] [Abstract][Full Text] [Related]
17. Intronic single nucleotide polymorphisms in the RET protooncogene are associated with a subset of apparently sporadic pheochromocytoma and may modulate age of onset.
McWhinney SR; Boru G; Binkley PK; Peczkowska M; Januszewicz AA; Neumann HP; Eng C
J Clin Endocrinol Metab; 2003 Oct; 88(10):4911-6. PubMed ID: 14557473
[TBL] [Abstract][Full Text] [Related]
18. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
19. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma.
Jindrichova S; Kodet R; Krskova L; Vlcek P; Bendlova B
J Mol Med (Berl); 2003 Dec; 81(12):819-23. PubMed ID: 14618242
[TBL] [Abstract][Full Text] [Related]
20. Immunostaining and RT-PCR: different approaches to search for RET rearrangements in patients with papillary thyroid carcinoma.
Rebelo S; Domingues R; Catarino AL; Mendonça E; Santos JR; Sobrinho L; Bugalho MJ
Int J Oncol; 2003 Oct; 23(4):1025-32. PubMed ID: 12963982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
